Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) Research & Development (2019 - 2025)

Black Diamond Therapeutics' Research & Development history spans 5 years, with the latest figure at $6.3 million for Q4 2025.

  • For Q4 2025, Research & Development fell 48.8% year-over-year to $6.3 million; the TTM value through Dec 2025 reached $33.6 million, down 34.6%, while the annual FY2025 figure was $33.6 million, 34.6% down from the prior year.
  • Research & Development reached $6.3 million in Q4 2025 per BDTX's latest filing, down from $7.4 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $27.6 million in Q3 2021 to a low of $6.3 million in Q4 2025.
  • Average Research & Development over 3 years is $14.7 million, with a median of $12.6 million recorded in 2024.
  • Peak YoY movement for Research & Development: surged 210.31% in 2021, then plummeted 48.8% in 2025.
  • A 3-year view of Research & Development shows it stood at $27.6 million in 2021, then tumbled by 55.49% to $12.3 million in 2024, then crashed by 48.8% to $6.3 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Research & Development are $6.3 million (Q4 2025), $7.4 million (Q3 2025), and $9.3 million (Q2 2025).